TITLE

COMPANY SPOTLIGHT - Merck KGaA

PUB. DATE
January 2007
SOURCE
PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p41
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on a joint venture between Merck KGaA and Chi-Med, both a pharmaceutical company, in developing treatments for cancer with traditional Chinese medicine. The two companies have agreed to develop small molecule anti-cancer drugs using 10,000 natural substances from Chi-Med to help manufacture the products. Moreover, Chi-Med believes that traditional Chinese medicine is a major, under-exploited reservoir for the development of novel drugs for the global pharmaceutical market.
ACCESSION #
24004021

 

Related Articles

  • COMPANY SPOTLIGHT - Merck KGaA.  // PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p19 

    The article focuses on the joint venture of German drug maker Merck KGaA and Chinese pharmaceutical company Chi-Med concerning the development of new treatments for cancer in the pharmaceutical industry. The two companies reach into an agreement that Merck will develop new treatments for cancer...

  • A Chinese. Beacham, Will // ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p3 

    The article discusses the use of traditional Chinese medicines by big pharmaceutical companies in search of new chemicals for the drugs. As stated big pharmaceutical companies are collaborating with Asian counterparts supplying Chinese medicines to be used by the western laboratories in drug...

  • Drug & Device Pipeline News.  // CenterWatch Weekly;11/16/2015, Vol. 19 Issue 45, p7 

    A chart is presented depicting the trial status of the drug and device pipeline of several global pharmaceutical companies, including Hutchison China MediTech Ltd., Cymabay Therapeutics Inc. and Kite Pharma Inc.

  • Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 12, p158 

    The article reports on the 50-50 joint venture (JV) between Hutchison China MediTech Ltd. (Chi-Med) and Nesté Health Science Inc. (NHS) for research, development, and commercialisation of medicines and nutritional products. It says that JV to be named Nutrition Science Partners will focus on...

  • Merck KGaA to Close Sites, Outsource New Biopharma Drugs. Alperowicz, Natasha // Chemical Week;11/6/2002, Vol. 164 Issue 44, p35 

    Presents updates on the plans of Merck KGaA company for its operations as of November 6, 2002. Information on its plan to rationalize its drugs manufacturing operations; Details of its plans to increase its overall ethical pharmaceutical sales; Plans for its generics business.

  • Merck KGaA applies for approval of Erbitux in Europe.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p13 

    Announces that Merck KGaA has applied for approval of Erbitux in Europe indicated for metastatic colorectal cancer. Approval sought for the drug as a monotherapy and in combination with the standard chemotherapy irinotecan.

  • ImClone and Bristol-Myers sign co-development deal with Merck.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p13 

    The article reports on the agreement between ImClone Systems Inc. and Bristol-Myers Squibb Co. with Merck KGaA for the co-development and co-commercialization of cancer drug Erbitux in Japan. According to the agreement, the companies will develop Erbitux for the treatment of epidermal growth...

  • Merck completes Japanese acquisition.  // Pharmaceutical Technology Asia;Apr2002, p6 

    Reports on the completion of the acquisition of generic drug company Mohan Medicine Research Institute of Tokyo, Japan by the Merck Generics Group. Purpose of the acquisition; Expectations of Merck from the acquisition; Information on generic drug sales in Japan, as of April 2002.

  • Merck KGaA Drops Plans for Biologics Unit. Scott, Alex // Chemical Week;11/26/2003, Vol. 165 Issue 43, p32 

    Focuses on the decision of Merck KGaA to drop its plans to build a factory that will produce Erbitux and other humanized antibody drugs at Hena, Germany as of November 2003. Reason behind the cancellation; Benefits of the move; Plan of Merck to restructure its pharmaceutical business in France.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics